Professor of Medicine, USC School of Medicine
Oncology
Dr. Cary A. Presant, MD
|
|
Give Review
Cary Presant works in the field of Oncology. He went to medical school at University at Buffalo, School of Medicine and Biomedical Sciences. He received 5 awards: "Top Doctors:LA Area", "CMS Meaningful Use Stage 1 Certification", "Top Doctors:Southern California", "Fellow (FASCO)" and "Super Doctor". Cary A. Presant has written publications. He has 101 publications published with PubMed. The lastest paper is: 'Amphotericin B plus 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU-NSC no. 409962) in advanced cancer. Phase I and preliminary phase II results.' Doctor Cary A. Presant, MD is registered with Medicare and accepts Medicare payments.
Publications
- Correlation of the microculture-kinetic drug-induced apoptosis assay with patient outcomes in initial treatment of adult acute myelocytic leukemia.
- The Microculture-Kinetic (MiCK) Assay: The Role of a Drug-Induced Apoptosis Assay in Drug Development and Clinical Care.
- A copay foundation assistance support program for patients receiving intraVenous cancer therapy.
- Implementing EHRs in community oncology practices.
- Aromatase inhibitor-associated arthralgia and/ or bone pain: frequency and characterization in non-clinical trial patients.
- Effects of weekly paclitaxel or paclitaxel plus carboplatin on functionality and symptoms of geriatric patients with cancer as measured by a brief geriatric oncology m...
- Tumor-based pharmacokinetics has greater significance for anticancer drugs than does blood-based pharmacokinetics.
- Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer.
- Human chorionic gonadotropin and malignant mesothelioma.
- Phase II trial of piperazinedione in malignant melanoma: a report by the Southeastern Cancer Study Group.
- Adriamycin, 1,3-bis (2-chloroethyl) 1 nitrosourea (BCNU, NSC No. 409962), cyclophosphamide plus prednisone (ABC-P) in melphalanresistant multiple Myeloma.
- Prognostic significance of thrombocytosis in idiopathic sideroblastic Anemia.
- Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC 409962) and cyclophosphamide therapy of drug-resistant metastatic breast carcinoma.
- Severe myelosuppression from piperazinedione, (NSC No. 135758), cyclophosphamide plus dimethyl-triazeno-imidazole carboxamide (DTIC).
- Influenza immunization of adult patients with malignant diseases.
- Amphotericin B plus 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU-NSC no. 409962) in advanced cancer. Phase I and preliminary phase II results.
- Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU-NSC 409462), and cyclophosphamide in refractory adenocarcinoma of the breast and other tumors.
- Tunneled central venous catheter complications and the iatrogenic superior vena cava Syndrome.
- OKT-3/cyclophosphamide up-regulation of peripheral blood killer-lymphocyte subsets in human cancer patients.
- Preliminary report: imaging of Kaposi sarcoma and Lymphoma in AIDS with indium-111-labelled liposomes.
- A phase II trial of continuous infusion vinblastine in patients with gastric carcinoma. A Southwest Oncology Group study.
- Human tumor fluorouracil trapping: clinical correlations of in vivo 19F nuclear magnetic resonance spectroscopy pharmacokinetics.
- Tumor trapping of 5-fluorouracil: in vivo 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits.
- Proposed criteria for serial evaluation of quality of life in cancer patients.
- Familial cancer genetic evaluation: introduction into a community cancer screening program.
- Sequentially administered 5-azacitidine and amsacrine in refractory adult acute leukemia: a phase I-II trial of the Southeastern Cancer Study Group.
- Cisplatin, vinblastine, and bleomycin in the treatment of metastatic melanoma: a phase II study of the Southeastern Cancer Study Group.
- Stress-relieving relaxation audio-tape for supportive care of cancer patients: developmental studies.
- Clinical responses with active specific intralymphatic immunotherapy for cancer--a phase I-II trial.
- Increased T-helper lymphocytes following active specific intralymphatic immunotherapy of cancer.
- Human immunodeficiency virus-associated T-cell lymphoblastic Lymphoma in AIDS.
- Buserelin treatment of advanced prostatic carcinoma. Long-term follow-up of antitumor responses and improved quality of life.
- Youth cancer education through a combined American Cancer Society-Boy Scouts of America pilot program.
- In-111-labeled liposomes: dosimetry and tumor depiction.
- Successful imaging of human cancer with indium-111-labeled phospholipid vesicles.
- Phase II trial of diaziquone in anthracycline-resistant adult soft tissue and bone sarcoma patients: a Southeastern Cancer Study Group Trial.
- Reversal of cancer chemotherapeutic resistance by amphotericin B--A broad phase I-II pilot study.
- Antiemetic effects of metoclopramide (M) continuous infusion (CI): safety, efficacy, patient preference, and cost reduction.
- Purging procedure eliminates antineoplastic drug solution spillage.
- Pilot phase II trial of amphotericin B and CCNU in renal and colorectal carcinomas.
- Verapamil reversal of clinical doxorubicin resistance in human cancer. A Wilshire Oncology Medical Group pilot phase I-II study.
- Soft-tissue and bone sarcoma histopathology peer review: the frequency of disagreement in diagnosis and the need for second pathology opinions. The Southeastern Cancer...
- Buserelin as primary therapy in advanced prostatic carcinoma.
- Phase I trial of misonidazole (NSC#261037) plus cyclophosphamide in solid tumors.
- A comparison of the antiemetic efficacy of prochlorperazine and metoclopramide for the treatment of cisplatin-induced emesis: a prospective, randomized, double-blind s...
- Phase II trial of etoposide, vincristine, and high-dose cisplatin in advanced non-small cell lung cancer.
- Effects of phenylalanine and related compounds on serum alkaline phosphatase assay.
- Characterization of the cell surface receptor for the Agaricus bisporus hemagglutinin.
- Gingival leukemic infiltration in chronic lymphocytic leukemia.
- Correlation of Anemia with infradiaphragmatic involvement in Hodgkin''s disease and other malignant lymphomas.
- Oxymetholone in myelofibrosis and chronic lymphocytic leukemia.
- Factors affecting survival in nocardiosis.
- Disseminated extrapulmonary nocardiosis presenting as a renal abscess.
- Selective renal arteriography in Hodgkin''s disease of the kidney. A case report.
- Sensitive radiochemical assay for inosine 5'-monophosphate dehydrogenase and determination of activity in murine tumor and tissue extracts.
- Contrasting cytotoxicity kinetics of 5-azacytidine and dihydro-5-azacytidine hydrochloride in L1210 leukemia in mice.
- Chemotherapy of L1210 leukemia with 5-azacytidine in combination with vincristine, adriamycin, or beta-cytosine arabinoside.
- Prognostic factors in metastatic malignant melanoma: The Southeastern Cancer Study Group Experience.
- Effects of amphotericin B with combination chemotherapy on response rates and on survival in non-small cell carcinoma of the lung.
- Phase II study of chlorozotocin in malignant melanoma: a Southeastern Cancer Study Group report.
- Continuous five-day infusion of PALA and 5FU: a pilot phase II trial.
- Phase II evaluation of chlorozotocin in metastatic sarcomas.
- Phase I study of continuous-infusion PALA and 5-FU.
- Phase II study of 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC No. 409962) with amphotericin B in bronchogenic carcinoma.
- Effects of amphotericin B on combination chemotherapy of metastatic sarcomas.
- Ineffectiveness of adjuvant chemotherapy using DTIC and cyclophosphamide in patients with resectable metastatic melanoma.
- Prospective randomized reappraisal of 5-fluorouracil in metastatic colorectal carcinoma. A comparative trial with 6-thioguanine.
- Quality of life in cancer patients. Who measures what?
- The effects of using Chemocap on occurrence of chemotherapy-induced alopecia.
- Quality of life index for patients with cancer.
- Neoplasia associated superior vena cava Syndrome.
- Adriamycin, BCNU, and cyclophosphamide in drug-resistant adenocarcinoma of the ovary.
- Iatrogenic superior vena cava Syndrome. A new entity.
- Treatment of metastatic sarcomas with mitoxantrone.
- Mitoxantrone in malignant melanoma.
- Liposomal blockade of the reticuloendothelial system: improved tumor imaging with small unilamellar vesicles.
- Tumor-imaging potential of liposomes loaded with In-111-NTA: biodistribution in mice.
- Thymidine and 5-FU: a Phase II pilot study in colorectal and breast carcinomas.
- Evaluating quality-of-life in oncology patients: pilot observations.
- Remission maintenance for acute nonlymphocytic leukemia: cytosine arabinoside plus 6-thioguanine versus a sequence of drug regimens.
- Implementation of adjuvant therapy for breast cancer in the St. Louis Metropolitan area: 1976-1977.
- A randomized prospective clinical trial of adjuvant C. parvum immunotherapy in 260 patients with clinically localized melanoma (Stage I): prognostic factors analysis a...
- A randomized comparison of cyclophosphamide, DTIC with or without piperazinedione in metastatic malignant melanoma.
- Phase II trial of piperazinedione in metastatic sarcoma.
- Combination chemotherapy for bronchogenic carcinoma with doxorubicin, BCNU, and cyclophosphamide (ABC): a pilot study of the Southeastern Cancer Study Group.
- Serum levels of carcinoembryonic antigen and a tumor-extracted carcinoembryonic antigen-related antigen in cancer patients.
- Metastatic sarcomas: chemotherapy with adriamycin, cyclophosphamide, and methotrexate alternating with actinomycin D, DTIC, and vincristine.
- Amphotericin B. New perspectives.
- Amphotericin B (FungiZone R) enhancement of nitrogen mustard uptake by human tumor cells.
- Chemotherapy of advanced prostatic cancer with adriamycin, BCNU, and cyclophosphamide.
- Phase I and preliminary phase II observations of high-dose intermittent 6-thioguanine.
- Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncolo...
- Association of intratumoral pharmacokinetics of fluorouracil with clinical response.
- Liposomal daunorubicin treatment of HIV-associated Kaposi''s sarcoma.
- Clinical responses to intralymphatic whole-cell melanoma vaccine augmented by in vitro incubation with alpha-interferon.
- 5-Fluorouracil revisited: a new perspective for treatment planning.
- Non-invasive 19F-NMRS of 5-fluorouracil in pharmacokinetics and pharmacodynamic studies.
- Phase I/II trial of human recombinant granulocyte-colony-stimulating factor (filgrastim) and escalating doses of cyclophosphamide, mitoxantrone, and 5-FU in the treatm...
- Re-evaluation of benefits of BRCA1/2 testing.
- Enhancement of fluorouracil uptake in human colorectal and gastric cancers by interferon or by high-dose methotrexate: An in vivo human study using noninvasive (19)F-m...
Schools
University At Buffalo State University Of New York School Of Medicine
Presby Hospital Columbia PampS
Barnes Jewish Hospital
National Cancer Institute
Washington University
Conditions Treated
- Anemia
- Antiphospholipid Syndrome (APS)
- Coagulation Disorders (incl. Hemophilia)
- Deep Vein Thrombosis (DVT)
- View All
Doctors Specialties
- Hematology
- Oncology
Accepted Insurances
Awards
- Top Doctors:LA Area
- CMS Meaningful Use Stage 1 Certification
- Top Doctors:Southern California
- Fellow (FASCO)
- Super Doctor
Education
-
Washington University - Barnes-Jewish Hospital -
New York Presbyterian Hospital - Columbia Campus -
University at Buffalo, School of Medicine and Biomedical Sciences
Drug Facts
| NPI NUMBER | 1538109517 | |
| NPPES Provider LastName | PRESANT | |
| NPPES Provider FirstName | CARY | |
| NPPES Provider ZIPCode | 917903961 | |
| NPPES Provider State | CA | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 713.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 12.0 | |
| Percent Opioid Claims | 1.68 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1538109517 |
| Last Name Of The Provider | PRESANT |
| First Name Of The Provider | CARY |
| View All |
Similar Doctors
|
|
Dr. Subhash Dhand, MD
 This Doctor is OpenDoctor Recommended.
|